PPBT Stock Overview
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Purple Biotech Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪0.20 |
| 52 Week High | ₪0.79 |
| 52 Week Low | ₪0.18 |
| Beta | 0.57 |
| 1 Month Change | -17.62% |
| 3 Month Change | -13.73% |
| 1 Year Change | -71.16% |
| 3 Year Change | -86.52% |
| 5 Year Change | -94.89% |
| Change since IPO | -99.89% |
Recent News & Updates
Recent updates
We're A Little Worried About Purple Biotech's (TLV:PPBT) Cash Burn Rate
Mar 07
Can Purple Biotech (TLV:PPBT) Afford To Invest In Growth?
Oct 30Will Purple Biotech (TLV:PPBT) Spend Its Cash Wisely?
Jul 17Here's Why We're Watching Purple Biotech's (TLV:PPBT) Cash Burn Situation
Mar 13Is Purple Biotech (TLV:PPBT) In A Good Position To Deliver On Growth Plans?
Nov 27Is Purple Biotech (TLV:PPBT) In A Good Position To Deliver On Growth Plans?
Jul 21Purple Biotech (TLV:PPBT) Is In A Good Position To Deliver On Growth Plans
Mar 25Companies Like Purple Biotech (TLV:PPBT) Are In A Position To Invest In Growth
Dec 09Purple Biotech (TLV:PPBT) Is In A Good Position To Deliver On Growth Plans
May 28We Think Purple Biotech (TLV:PPBT) Can Afford To Drive Business Growth
Feb 11
If You Had Bought Purple Biotech's (TLV:KTOV) Shares Five Years Ago You Would Be Down 90%
Dec 21Shareholder Returns
| PPBT | IL Pharmaceuticals | IL Market | |
|---|---|---|---|
| 7D | 6.9% | 8.0% | 2.9% |
| 1Y | -71.2% | -11.2% | 10.8% |
Return vs Industry: PPBT underperformed the IL Pharmaceuticals industry which returned -14.7% over the past year.
Return vs Market: PPBT underperformed the IL Market which returned 10.7% over the past year.
Price Volatility
| PPBT volatility | |
|---|---|
| PPBT Average Weekly Movement | 12.6% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IL Market | 8.3% |
| 10% least volatile stocks in IL Market | 3.1% |
Stable Share Price: PPBT's share price has been volatile over the past 3 months.
Volatility Over Time: PPBT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 20 | Gil Efron | purple-biotech.com |
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy.
Purple Biotech Ltd Fundamentals Summary
| PPBT fundamental statistics | |
|---|---|
| Market cap | ₪53.38m |
| Earnings (TTM) | -₪74.91m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs PPBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PPBT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$196.00k |
| Gross Profit | -US$196.00k |
| Other Expenses | US$19.68m |
| Earnings | -US$19.88m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.075 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PPBT perform over the long term?
See historical performance and comparison